Hold control (command on a Mac) and press the + key as many times as necessary to increase the font size.
Hold control (command on a Mac) and press the - key to reduce the font size. - hide


Below is a summary of our recent news.  Click any post title or the read more link below any story to see more!

Neuropsychiatric Symptoms and Graves'

Posted 11 months ago

If you enjoyed the GDATF's patient bulletin "What's Wrong With Me? I'm Not Myself Anymore", then you won't want to miss the sequel! "A survey study of neuropsychiatric complaints in patients with Graves’ disease: A reassessment of self-reported symptoms and current practice 20 years later" is now available as an e-manuscript that is free with Kindle Unlimited or $2.99 with Amazon. Many thanks to Dr. James Arruda for conducting this important research - and for donating 70% of the proceeds to the GDATF! Click here for more info!

view full story / 0 comments

Patient Education Event in Seattle on June 30th - Register Today!

Posted 1 year ago

We're headed to Seattle! Please join us for a special patient education event on Sunday, June 30th from 8:30 a.m. until 4:30 p.m.! This event is FREE, but advance registration is reqired to reserve space. Please click here to view the agenda or click here for location and registration!

view full story / 0 comments

Top Line Teprotumumab Phase III Trial Results Released

Posted 1 year, 3 months ago

Horizon Pharma has just released top line results for the Phase III trial of Teprotumumab, a potential new treatment for thyroid eye disease. Detailed Phase III data will be submitted for publication in a peer-reviewed journal and presented at a medical congress later this year. Click this link to learn more: http://bit.ly/2ECfINj

Raymond Douglas, M.D., Ph.D., the study’s co-principal investigator, director of the orbital and thyroid eye disease program at Cedars-Sinai Medical Center, and a member of the GDATF's Physician Advisory Board stated: “In the study, patients treated with teprotumumab had an unprecedented reduction in proptosis [eye bulging], which is currently only treatable via surgery after the active disease has ended. If approved, teprotumumab would give physicians the first medicine shown to reduce proptosis during active thyroid eye disease, in addition to treating other painful symptoms.”

view full story / 0 comments

Registration Open for Los Angeles Patient Event!

Posted 1 year, 3 months ago

If you are in the Los Angeles area and would like to learn more about Graves' disease, pease join us for a special "Ask the Experts" session co-hosted by the American Association of Endocrine Surgeons and the Graves' Disease and Thyroid Foundation

view full story / 0 comments

Los Angeles Patient Education Event!

Posted 1 year, 3 months ago

If you are in the Los Angeles/Santa Monica area, please save the date for Saturday, April 6th from 5:00-6:30 PM at the Fairmont Miramar Hotel! The GDATF is pleased to be partnering with the American Association of Endocrine Surgeons on a FREE patient education event in conjunction with the AAES Annual Meeting! More details and registration info to come!

view full story / 0 comments

Page 3 of 20:

Questions? Problems? Please contact us at [email protected] or 877-643-3123.

Support the GDATF and become a member today!

© 2020 Graves' Disease & Thyroid Foundation